Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI Therapy Based on BCR/ABL Monitoring in Ph+ ALL Post-Transplant
NCT01883219Phase 2Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2013
- Primary completion
- Jun 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib, dasatinib, nilotinib and ponatinib in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Overall Survival at 2 years. Status: unknown.
02
Drugs
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT01883219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01883219.